Stemtech Corporation to Present at the Emerging Growth Conference on Wednesday, September 29, 2021 – Yahoo Finance

Stemtech invites individual and institutional investors as well as advisors and analysts, to attend its real-time, interactive presentation at the Emerging Growth Conference

MIRAMAR, Fla., Sept. 28, 2021 (GLOBE NEWSWIRE) -- Stemtech Corporation (Symbol: GNTW), a leading nutraceutical company and a pioneer in the field of stem cell nutrition, is pleased to announce that it has been invited to present at the Emerging Growth Conference on Wednesday, September 29, 2021.

The Emerging Growth Conference is a live, interactive online event will give existing shareholders and the investment community the opportunity to interact with the Companys COO, John W. Meyer, in real time.

Mr. Meyer will provide a presentation and may subsequently open the floor for questions. Please ask your questions during the event and Mr. Meyer will do his best to get through as many of them as possible.

Stemtech will be presenting at 11:00 AM Eastern time for 30 minutes.

Click the link to register for free conference attendance:https://goto.webcasts.com/starthere.jsp?ei=1487780&tp_key=8c67ce781e&sti=gntw

Please register here to ensure you are able to attend the conference and receive any updates that are released.

If attendees are not able to join the event live on the day of the conference, an archived webcast will also be made available on EmergingGrowth.com and we will also release a link to that after the event.

About the Emerging Growth Conference The Emerging Growth conference is an effective way for public companies to present and communicate their new products, services and other major announcements to the investment community from the convenience of their office, in a time efficient manner.

The Conference focus and coverage includes companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long term growth. Its audience includes potentially tens of thousands of Individual and Institutional investors, as well as Investment advisors and analysts.

Story continues

All sessions will be conducted through video webcasts and will take place in the Eastern time zone.

About Stemtech Corporation

Stemtech Corporation, a leading nutraceutical company with a direct sales distribution model, was founded on April 18, 2018, after acquiring the operations from its predecessor Stemtech International, Inc. which was founded in 2005. From 2010 through 2015, Stemtech International, Inc., was recognized four separate times on the Inc. 5000 Fastest-Growing Companies list. In 2018, the Company underwent an extensive executive reorganization, and continued operations under new leadership. Stemtech specializes in creating products and formulas that are patent-protected in the U.S. and in select international markets. The Companys patented formulas help the release, circulation and migration of the bodys adult stem cells from its bone marrow. The Company markets its products under the following brands: RCM System, stemrelease3, Stemflo MigraStem, OraStem (Oral Health Care), and D-Fuze. Its nutraceutical products are all-natural and plant-based and manufactured under cGMP (Current Good Manufacturing Practices) under the auspices of the Dietary Supplemental Health and Education Act (DSHEA). For more information, please visit http://www.stemtech.com.

Forward-Looking Statements

This announcement contains forward-looking statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Such statements include but are not limited to statements identified by words such as "believes," "expects," "anticipates," "estimates," "intends," "plans," "targets," "projects" and similar expressions. The statements in this release are based upon the current beliefs and expectations of our company's management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements. Numerous factors could cause or contribute to such differences, including, but not limited to, results of clinical trials and/or other studies, the challenges inherent in new product development initiatives, the effect of any competitive products, our ability to license and protect our intellectual property, our ability to raise additional capital in the future that is necessary to maintain our business, changes in government policy and/or regulation, potential litigation by or against us, any governmental review of our products or practices, as well as other risks discussed from time to time in our filings with the Securities and Exchange Commission, including, without limitation, our latest 10-Q filed July 13th, 2021. We undertake no duty to update any forward-looking statement, or any information contained in this press release or in other public disclosures at any time. Finally, the investing public is reminded that the only announcements or information about Stemtech Corporation which are condoned by the Company must emanate from the Company itself and bear our name as its Source.

Contact: Frank Pena (fpena@stemtech.com) Ph: 908-675-0581

Continued here:

Stemtech Corporation to Present at the Emerging Growth Conference on Wednesday, September 29, 2021 - Yahoo Finance